China's First Expert Consensus on Clinical Drug Treatment of Osteoarthritis Releases Key Products of Peak Pharmaceutical Yueyining Selected
Release time:
2021-07-21
News from our newspaper # February 10 , the Sports Medical Branch of the Chinese Medical Association and other units jointly released the "Expert Consensus on Clinical Drug Treatment of Osteoarthritis" in Hangzhou. This is the first time that the Chinese medical community has released osteoarthritis. Related expert consensus. Peak Pharmaceuticals' key product, Yue Yining (Aceclofenac Sustained Release Tablets), is included in the consensus list of therapeutic drugs.
"Expert Consensus on Clinical Drug Treatment of Osteoarthritis" was initiated by Chen Shiyi, winner of the "Chinese Medicine Award", director of the Sports Medicine Center of Fudan University, and director of the Orthopedic Arthroscopic Diagnosis and Treatment Technology Training Base of the Ministry of Health (Shanghai), the sports medicine branch of the Chinese medical association, the sports medicine group of the orthopaedic branch of the Chinese medical association, the arthroscopic society of the orthopaedic branch of the Chinese medical association and other units organized more than 30 relevant experts to jointly compile it, which took nearly 1 years to complete. the consensus is divided into 6 parts, and the full text is nearly 2 words. The experts participating in the discussion are distributed in 27 large-scale tertiary hospitals in 16 provinces (cities, autonomous regions) across the country, involving multiple disciplines such as orthopedics, sports medicine, pain, pharmacy, and evidence-based medicine. The formulation principles of rigorous, standardized, objective, practical, and economical, adhere to the guidance of evidence-based medicine, and fully integrate the current clinical practice of osteoarthritis in China, give more than 20 best clinical medication plan.
Yueyining (Aceclofenac Sustained Release Tablets), a key product of Jianfeng Pharmaceutical, has been recognized by experts and included in the consensus by virtue of its unique advantages. In the consensus, it is clearly pointed out that patients with osteoarthritis should choose the non-steroidal anti-inflammatory drug aceclofenac, which can promote the synthesis of cartilage matrix proteoglycan, and the slow-release dosage form can be preferred, which can better control the blood concentration and improve the compliance of patients with drugs.
According to introduction, osteoarthritis is prone to occur in middle-aged and elderly people with high incidence rate. More than 50% of knee pain people over 65 years old are osteoarthritis patients, and the prevalence rate of osteoarthritis in knee pain people over 75 years old exceeds 80% . With the promotion of national centralized procurement and disease diagnosis related sub-group (DRG) payment, the price of artificial joints has dropped significantly, and doctors and the business community are faced with the choice of surgery and medication, so the launch of this consensus is timely. According to the national standardization requirements for disease treatment, both conservative treatment and drug treatment need corresponding guiding principles, which are based on guidelines and expert consensus. On the basis of being included in the expert consensus this time, Jianfeng Pharmaceutical will make every effort to carry out the promotion of the "Expert Consensus on Clinical Drug Treatment of Osteoarthritis" to further guide the safe, effective, economical and standardized use of osteoarthritis treatment drugs in clinical practice. Highlight the clinical advantages of Yueyining and better expand the market of this product.
(Xu Yuting)
More information
The company's vocational skill level independently identifies two new occupations
A few days ago, after the examination and approval of the Jinhua Municipal Bureau of Human Resources and Social Security, and reported to the Provincial Department of Human Resources and Social Security for examination and filing, Jianfeng Group's independent identification level of vocational skills was based on last year. Two new occupations (types of work) are chemical inspectors and organic synthesis workers.
2022
05-20
On May 12, Cai Xiaochun, deputy secretary of the Party group of Zhejiang Federation of industry and commerce, and his party visited Jianfeng group for investigation, visited Jinxi factory area of Jianfeng pharmaceutical factory and Jinxi internationalization project site, and had a discussion with Jiang Xiaomeng, chairman of the group company, Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company.
2022
05-20
On the afternoon of April 6, Jiang Xiaomeng, chairman of the group company, was invited to participate in the Jinhua News Client Financial Media Interview column "Night Talk of the Two Sessions", as a representative of the Jinhua Municipal People's Congress, to talk about suggestions for the future development of Jinhua enterprises. As the chairman of the Jinhua City Federation of Industry and Commerce, Jiang Xiaomeng has a personal experience of various problems encountered in the development of Jinhua enterprises. After careful investigation and full preparation, he put forward two proposals on strengthening the empowerment and allocation of production factors and further enhancing the market competitiveness of enterprises in our city and further promoting the compliance construction of private enterprises in our city and reducing the risk of enterprise operation. In the "two sessions night talk" interview, he put forward his own views on these two topics.
2022
04-12
Group Companies Commend 2021 Advanced
On the morning of January 26, the group company held the 2021 annual summary commendation meeting to review the work of the previous year, make arrangements for the work of 2022, sign the 2022 economic responsibility system with various professional companies and directly affiliated enterprises, and solemnly commend the 2021 advanced collectives and individuals.
2022
02-08
Group Company Convenes Workers' Representative and Trade Union Member Representative Conference
The group company held a representative meeting of staff representatives and trade union members, elected members of the eighth trade union committee and members of various special committees, and Shi Fu was elected chairman of the eighth trade union of the group trade union.
2022
02-08
The group company held an annual safety and environmental protection work conference to comprehensively summarize and review the safety and environmental protection work in 2021, make arrangements for the safety and environmental protection work in 2022, and sign the safety and environmental protection work responsibility system.
2022
02-08
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page